Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/81286
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance
Author: Parker, W.
Yeoman, A.
Jamison, B.
Yeung, D.
Scott, H.
Hughes, T.
Branford, S.
Citation: British Journal of Cancer, 2013; 109(6):1593-1598
Publisher: Nature Publishing Group
Issue Date: 2013
ISSN: 0007-0920
1532-1827
Statement of
Responsibility: 
W T Parker, A L Yeoman, B A Jamison, D T Yeung, H S Scott, T P Hughes, and S Branford
Abstract: BACKGROUND: BCR-ABL1 mutation analysis is recommended for chronic myeloid leukaemia patients. However, mutations may become undetectable after changing therapy, and it is unknown whether they have been eradicated. METHODS: We examined longitudinal data of patients with imatinib-resistant mutations, which became undetectable by Sanger sequencing to determine whether mutations could reappear, and the related circumstances. RESULTS: Identical imatinib- and nilotinib-resistant mutations reappeared following further therapy changes in five patients, and was associated with subsequent nilotinib resistance in four. CONCLUSION: The data suggest that some BCR-ABL1 mutations may persist at undetectable levels for many years after changing therapy, and can be reselected and confer resistance to subsequent inhibitors.
Keywords: chronic myeloid leukaemia; mutation analysis; tyrosine kinase inhibitor; resistance
Rights: © 2013 Cancer Research UK. All rights reserved.
RMID: 0020131959
DOI: 10.1038/bjc.2013.318
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.